Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 97, Issue 2, 2012, Pages 258-266

  Horowitz, Michael ^a   Flint, Anne ^b   Jones, Karen L ^a   Hindsberger, Charlotte ^b   Rasmussen, Mads F ^b   Kapitza, Christoph ^c   Doran, Selena ^a   Jax, Thomas ^c   Zdravkovic, Milan ^b   Chapman, Ian M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b NOVO NORDISK A S   (Denmark)

^c Profil Institut fur Stoffwechselforschung GmbH   (Germany)

Author keywords

Appetite; Energy intake; Gastric emptying; Glucagon like peptide 1; Liraglutide

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GHRELIN; GLIMEPIRIDE; GLUCOSE; LIRAGLUTIDE; PARACETAMOL; PEPTIDE YY; PLACEBO;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANTRAL DISTENTION; APPETITE; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENERGY EXPENDITURE; EVENING DOSAGE; FEMALE; GASTROINTESTINAL PAIN; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HUNGER; HYPOGLYCEMIA; MACRONUTRIENT DISTRIBUTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAL DURATION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL PARAMETERS; RANDOMIZED CONTROLLED TRIAL; RESTING ENERGY EXPENDITURE; STOMACH DISTENSION; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; APPETITE; AUSTRALIA; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; ENERGY INTAKE; ENERGY METABOLISM; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OBESITY; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 84865070709     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2012.02.016     Document Type: Article

References (47)

1. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
2. Gutzwiller J.P., Drewe J., Goke B., et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999, 276:R1541-R1544.
3. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
4. Flint A., Raben A., Ersboll A.K., Holst J.J., Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes 2001, 25:781-792.
5. Larsen J. Glucagon-like peptide-1 infusion must be maintained for 24h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. Diabetes Care 2001, 24:1416-1421.
6. Shalev A., Holst J.J., Keller U. Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 1997, 27:10-16.
7. Flint A., Kapitza C., Hindsberger C., Zdravkovic M. The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients. Adv Ther 2011, 28:213-226.
8. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
9. Degn K.B., Juhl C.B., Sturis J., et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.
10. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
11. Garber A., Henry R., Ratner R., et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009, 373:473-481.
12. Marre M., Shaw J., Brandle M., et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
13. Nauck M., Frid A., Hermansen K., et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care 2009, 32:84-90.
14. Russell-Jones D., Vaag A., Schmitz O., et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
15. Zinman B., Gerich J., Buse J., et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009, 32:1224-1230.
16. Astrup A., Rossner S., Van Gaal L., et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374:1606-1616.
17. Sturm K., Parker B., Wishart J., et al. Energy intake and appetite are related to antral area in healthy young and older subjects. Am J Clin Nutr 2004, 80:656-667.
18. Stunkard A.J., Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res 1985, 29:71-83.
19. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Last amended by the 59th WMA Assembly, Seoul, October 2008. Accessed 1 November 2011. http://www.wma.net/en/30publications/10policies/b3/.
20. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice. 01 May 1996. Accessed 1 November 2011. http://www1.cgmh.org.tw/intr/intr1/c0040/web/C/ICH%20GCP%20E6.pdf.
21. Willems M., Quartero A.O., Numans M.E. How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study. Dig Dis Sci 2001, 46:2256-2262.
22. Chapman I., Parker B., Doran S., et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005, 48:838-848.
23. Flint A., Raben A., Blundell J.E., Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000, 24:38-48.
24. Little J., Pilichiewicz A., Russo A., et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 2006, 91:1916-1923.
25. Hveem K., Jones K.L., Chatterton B.E., Horowitz M. Scintigraphic measurement of gastric emptying and ultrasonographic assessment of antral area: relation to appetite. Gut 1996, 38:816-821.
26. Jones K.L., Doran S.M., Hveem K., et al. Relation between postprandial satiation and antral area in normal subjects. Am J Clin Nutr 1997, 66:127-132.
27. Hausken T., Berstad A. Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride. Scand J Gastroenterol 1992, 27:427-432.
28. Weir J.B. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949, 109:1-9.
29. Edwards C.M., Stanley S.A., Davis R., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001, 281:E155-E161.
30. Verdich C., Flint A., Gutzwiller J.P., et al. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 2001, 86:4382-4389.
31. Turton M.D., O'Shea D., Gunn I., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
32. Hayes M.R., Kanoski S.E., Alhadeff A.L., Grill H.J. Comparative effects of the long-acting glp-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats. Obesity (Silver Spring) 2011, 19:1342-1349.
33. Schirra J., Nicolaus M., Roggel R., et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006, 55:243-251.
34. Schvarcz E., Palmer M., Aman J., Horowitz M., Stridsberg M., Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997, 113:60-66.
35. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
36. Russell A.W., Horowitz M., Ritz M., MacIntosh C., Fraser R., Chapman I.M. The effect of acute hyperglycaemia on appetite and food intake in Type 1 diabetes mellitus. Diabet Med 2001, 18:718-725.
37. Deane A.M., Nguyen N.Q., Stevens J.E., et al. Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 2010, 95:215-221.
38. DeFronzo R.A., Okerson T., Viswanathan P., Guan X., Holcombe J.H., MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
39. Linnebjerg H., Park S., Kothare P.A., et al. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul Pept 2008, 151:123-129.
40. Batterham R.L., Cowley M.A., Small C.J., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418:650-654.
41. Raun K., Von-Voss P., Gotfredsen C.F., Golozoubova V., Rolin B., Knudsen L.B. Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 2007, 56:8-15.
42. Vahl T.P., Tauchi M., Durler T.S., et al. Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 2007, 148:4965-4973.
43. Abbott C.R., Monteiro M., Small C.J., et al. The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 2005, 1044:127-131.
44. Rüttimann E.B., Arnold M., Hillebrand J.J., Geary N., Langhans W. Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms. Endocrinology 2009, 150:1174-1181.
45. Hayes M.R., Bradley L., Grill H.J. Endogenous hindbrain glucagon-like peptide-1 receptor activation contributes to the control of food intake by mediating gastric satiation signaling. Endocrinology 2009, 150:2654-2659.
46. Vrang N., Larsen P.J. Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides. Prog Neurobiol 2010, 92:442-462.
47. Vella A., Bock G., Giesler P.D., et al. Effects of dipeptidyl peptidase-4 inhibition on gastrointestinal function, meal appearance, and glucose metabolism in type 2 diabetes. Diabetes 2007, 56:1475-1480.